Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729414 | 0.95 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL19801496 | 0.89 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL22090106 | 0.89 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL14663974 | 0.88 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL2756433 | 0.88 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL14663969 | 0.88 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL25969984 | 0.85 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL8268640 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL30910214 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL25979949 | 0.84 | TSHR (0.41) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | HSD17B10 4428/4885SMN1; SMN2 524/4885NPC1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.